CD36 and hepatocellular carcinoma: When considering patients that were high for both CD36 and CD47, 11 out of 13 indications had more than 47% of cases with dual high levels of CD36/CD47, with Kidney Cancer (37%) and HCC (35%) as the exception (Fig. 2c).